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In the past decades, both the importance of inositol for human health and the complex interaction between glucose and inositol
have been the subject of increasing consideration. Glucose has been shown to interfere with cellular transmembrane transport of
inositol, inhibiting, among others, its intestinal absorption. Moreover, intracellular glucose is required for de novo biosynthesis
of inositol through the inositol-3-phosphate synthase 1 pathway, while a few glucose-related metabolites, like sorbitol, reduce
intracellular levels of inositol. Furthermore, inositol, via its major isomers myo-inositol and D-chiro-inositol, and probably some
of its phosphate intermediate metabolites and correlated enzymes (like inositol hexakisphosphate kinase) participate in both
insulin signaling and glucose metabolism by influencing distinct pathways. Indeed, clinical data support the beneficial effects
exerted by inositol by reducing glycaemia levels and hyperinsulinemia and buffering negative effects of sustained insulin
stimulation upon the adipose tissue and the endocrine system. Due to these multiple effects, myoIns has become a reliable
treatment option, as opposed to hormonal stimulation, for insulin-resistant PCOS patients.
1. Inositol and Insulin Signaling System
It is currently well known that diets providing high
amounts of fibers have a protective role in the manage-
ment (and prevention) of chronic diseases—namely those
characterized by deregulated glucose and insulin metabo-
lism [1, 2]. While consumption of highly refined diets is
frequently associated with increased risk for diabetes and
cancer [3], the effect of high-fiber diets is usually ascribed
to the presence of whole-grain cereal products and of a
plethora of phytochemicals, which display an astonishing
range of different biochemical-pharmacological effects, well
documented in in vitro and in vivo studies [4]. Among the
aforementioned constituents, inositol appears to occupy a
prominent position. Indeed, several investigations have
demonstrated that only fibers with high content in phytic
acid or phytate (inositol hexakisphosphate, InsP6) and its
derivative myo-inositol (myoIns) show negative correlation
with colon cancer and diabetes, indicating that inositol-
derived compounds can suppress colon carcinogenesis [5]
or improve glucose metabolism [6].
Indeed, several alterations in inositol metabolism have
been observed in insulin-resistant and diabetic patients
([7], reviewed in [8]). Namely, the decreased availability
of inositol or inositol phosphoglycans (IPGs) can be pri-
marily ascribed to increased urinary loss of myoIns in
both animals and humans with insulin resistance. This
effect is mostly due to the glucose-mediated inhibition of
myoIns reabsorption by the kidney. Reduction in myoIns
availability has a direct negative impact on the levels of
its D-chiro-inositol (DCIns) isomer. In turn, plasma and
intracellular depletion of myoIns and its isomers or IPG
metabolites is likely to worsen insulin resistance. In fact,
IPGs and probably myoIns itself are involved in the insu-
lin signaling machinery. Conversely, altered profiles of
plasma/urinary levels of inositol and its metabolites/
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isomers, including DCIns, have been observed in diabetes,
insulin resistance, or metabolic syndrome.
These findings boosted investigation on the involvement
of inositol in different physiological conditions, comprising
fertility [9], oogenesis [10], embryogenesis [11, 12] regenera-
tive processes [13], and fat metabolism [14].
It is currently acknowledged that some of the effects
ascribed to inositol can be explained by the ability of this
molecule or its metabolites to modulate glucose metabolism,
by transducing insulin effects downstream of insulin-
receptor (IR) coupling. Yet, the complex interplay among
insulin, glucose metabolism and inositol-related molecules
is still poorly understood and only a few surveys have been
hitherto performed to address such issue.
2. Inositol Availability and Dietary Supply
Inositol is chemically identified as hexahydroxycyclohexane
and consists of a family of 9 stereoisomers. MyoIns is the
most widely distributed representative of this family in
nature, including animals and mammals [15]. A normal diet
provides inositols, mainly present in cereals and legumes, as
myoIns, for the most part, phosphatidylinositol (PI) and
InsP6 [16]. Inositol has been shown to be essential for cell
growth and has been considered for a long time as a compo-
nent of the vitamin B family [17, 18]. However, we now
know that the human body (especially the liver and brain)
[19] can produce up to 4 g/day inositol, and that assumption
is no longer recognized.
Indirect estimates of the availability of myoIns in human
diet, based on the consumption of phytate-rich food, reveal
daily intakes not exceeding 500–700mg/day for western
countries, with higher consumption rates in Africa and Asia.
In Italy, for example, available estimates of the mean value of
phytic acid intake range from 219 to 293mg/day [20, 21]. In
the USA and Canada, average phytic acid intake is of 538mg/
day in adults, with relevant differences between males and
females (608mg vs 512mg/day, respectively) [22], and of
170–390mg/day in children [23].
3. Glucose and Inositol Biosynthesis
As anticipated, myoIns is actively synthetized by living
cells. We do not know if this biosynthetic activity makes
our body independent of dietary inositol supply, but an
idea of how relevant inositol biosynthesis can be in some
tissues comes from observations on the brain, which pro-
duces myoIns at concentrations reaching 10- to15-fold
the values measured in circulating blood, with only limited
“extracting” ability [24].
The cellular precursor of myoIns is glucose-6-phosphate
(G6P), which is isomerized to inositol-3-phosphate (Ins3P)
by D-3-myo-inositol-phosphate synthase (inositol synthase,
Ino1 or MIPS1), an enzyme encoded by the evolutionarily
conserved Ino1 and Isyna1 genes in yeast and mammals,
respectively [24]. Inositol-3-phosphate is then dephosphory-
lated to free myoIns by inositol monophosphatase-1 (IMPA-
1 or IMPase) [25]. Free inositol may also be obtained by
recycling inositol-1,4,5-trisphosphate (InsP3) and inositol-
1,4-bisphosphate (InsP2).
MyoIns biosynthesis varies among tissues depending on
changing functional requirements. In yeast, Ino1 and
IMPA-1 are induced by low inositol levels [26] and downreg-
ulated by high inositol levels [27]. Both Ino1 and Isyna1 can
be epigenetically modified [28] and mammalian Isyna1
exhibits gender- and tissue-specific DNA methylation
patterns [29] that modulate inositol biosynthesis.
In mammalian cells, however, intracellular myoIns avail-
ability seems ineffective in controlling Isyna1 activity [30],
the expression of which is downregulated by inositol pyro-
phosphates (IP7), produced by inositol hexakisphosphate
kinase (IP6K1) [31]. IP7 has been found to inhibit transcrip-
tion of Isyna1 by increasing its methylation levels [32]. A key
role in this pathway is played by phosphatidic acid (PA),
which increases nuclear translocation of IP6K1, thus
finally leading to decreased myoIns content. PA increases
when higher energy demand imposes high rates of glucose
catabolism [33], being synthesized from two glycolytic
intermediates—dihydroxyacetone phosphate and glycerol-
3-phosphate [34]. Furthermore, high glucose levels indi-
rectly increase the activity of phospholipase D (PLD), a
key enzyme for PA synthesis [35].
In mammalian cells, a positive regulator of Isyna1 tran-
scription is glycogen synthase kinase 3 (GSK3), since loss of
GSK3 activity causes myoIns depletion [36]. Furthermore,
synthesis of inositol is positively regulated by Mck1, a
GSK3 homolog required for normal activity of MIPS1, the
rate-limiting enzyme in inositol synthesis [37].
4. Influence of Glucose on Inositol Uptake
and Metabolism
Long ago, a negative association observed between phytic
acid intake and the glycemic index of cereals and legumes
consumed by humans led to a hypothesis of a correlation
among inositol, phytic acid, and glucose metabolism [38].
This was supported by further studies, which revealed that
removal of phytate from bean flour increases its glycemic
index [39] and that myoIns significantly inhibits duodenal
glucose absorption and reduces blood glucose rise, suggest-
ing the existence of a competitive affinity for the same
transporter system [40].
It now appears that a complex relationship between
glucose and myoIns does exist, and glucose can interfere with
myoIns metabolism at different levels.
In the first place, glucose significantly counteracts cellular
uptake of inositol. Inositol is transported intracellularly by
sodium ion-coupled transporters (SMIT1 and SMIT2) [41],
which are posttranslationally regulated through phosphory-
lation by both protein kinase A and protein kinase C [42],
and a proton-coupled transporter (HMIT1) [43].
In hepatocytes, inhibitors of the main sodium-glucose
transporters (SGLT) 1/2 prevent both glucose and inositol
uptake [44], suggesting that the two molecules share the
transporter system(s). Inositol uptake is also decreased by
glucose. MyoIns depletion in nervous tissues induced by
hyperglycemia depends on competitive inhibition of
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sodium ion-coupled myoIns transporters [45]. Inositol
uptake in cultured cells is also significantly inhibited by
20mM glucose [46].
Secondly, glucose may induce myoIns depletion by
activation of the glucose-sorbitol pathway, in which glucose
is first converted to sorbitol by aldose reductase and then to
fructose by sorbitol dehydrogenase, as observed in diabetic
patients [47]. The increased production of sorbitol pro-
duces a harmful rise in intracellular osmolarity, an event
counteracted by inhibition of the uptake of other relevant
osmolytes, including inositol, via downregulated expression
of their carriers [48]. Inhibiting aldose reductase in
cultured cells restores myoIns levels counteracting the
depleting effect of sorbitol [49].
Glucose-dependent depletion of normal levels of intra-
cellular inositol is further confirmed by observations
obtained on specific tissues, especially in those susceptible
of developing diabetes complications, of hyperglycemic
patients [50]. In addition, both hyperglycemia and insulin
resistance have been found to modify the relative ratio in
which different inositol isomers, especially myoIns and
DCIns (approximately 100 : 1), are present in these tissues
[51]. Changes in the ratio of plasma and urinary myoIns/
DCIns levels are so tightly linked to insulin abnormalities
to be considered an early marker of hyperglycemia and insu-
lin resistance [7]. This worsens insulin resistance and diabe-
tes complications, impairs cellular redox and free radical
defenses, and increases oxidative glycation stress [52, 53].
Under these circumstances, myoIns supplementation
reduces several diabetes symptoms and metabolic markers
of different pathologies [54].
5. Inositol Mechanisms of Action
A role for inositol and inositol-related metabolites in insulin
signaling emerged from the observation that, under insulin
stimulation and activation of a phosphatidyl-inositol-
specific phospholipase C, liver plasma membrane releases
inositol phosphoglycans (IPG) containing either myoIns
(IPG-A) or DCIns (IPG-P) [55]. While IPG-P (inositol
phosphoglycan-phosphatase stimulator) promotes the acti-
vation of pyruvate dehydrogenase (PDH) phosphatases
(PDHP) and PDH [56], IPG-A (inositol phosphoglycan-
AMP kinase inhibitor) inhibits both protein kinase A and
adenylyl cyclase (AC) [57, 58].
Both types of IPGs have been shown to exert an insulin-
mimetic activity, acting as second messengers downstream of
insulin receptors [56]. When administered to normal or dia-
betic rats, they reduce hyperglycemia in a dose-dependent
fashion and promote muscular glycogenesis [59]. Insulin
stimulates glycosyl-phosphatidylinositol (GPI) hydrolysis
through direct activation of phospholipase C (PLC) and
PLD, with production of water-soluble IPSs [60, 61]. Inositol
phosphoglycans also inhibit AC and protein kinase A with
antilipolytic and lipogenic effects [62].
Upon insulin receptor activation, IPGs are released out-
side the cell and reimported by an ATP-dependent inositol
glycan transporter [63], activating cytosolic phosphoprotein
phosphatase 2C-α (PP2Cα) and mitochondrial PDH. This
enhances oxidative glucose metabolism along the tricarbox-
ylic acid cycle. Activated PP2Cα stimulates glycogen synthase
(GS) both directly and indirectly, through the phosphatidyli-
nositide 3-kinase (PI3K)/Akt pathway [64]. Activation of Akt
inactivates glycogen synthase kinase-3 (GSK-3), enhancing
GS activity, and increases GLUT-4 translocation and glucose
uptake. Finally, as observed in the rat, IPG-P inhibits the
glucose-stimulated release of insulin from pancreatic β-cells,
suggesting the existence of a negative feedback mechanism in
this pathway [65]. On these bases, IPGs are supposed to exert
a general antidiabetic function.
The proper ratio at which IPG-A and IPG-P display the
most beneficial effects on insulin/glucose homeostasis is still
unclear, besides the fact that their contemporary presence
appears mandatory.
6. Hypotheses for Future Research
We would hypothesize that DCIns containing IPG is pref-
erentially synthetized during metabolic stress, in response
to increased insulin release. Indeed, upon insulin stimula-
tion, myoIns is converted by a specific epimerase into its
DCIns isomer. Epimerase activity is strictly dependent on
insulin, and shows a tissue-dependent modulation [66].
Inositol isomerization occurs at the phospholipid level
where (3H)-myoIns phospholipid are converted into
(3H)-DCIns as soon as 15 minutes after insulin stimula-
tion [67]. However, we cannot discard the possibility that
epimerization also occurs at the free inositol level, but
with the subsequent rapid incorporation of DCIns into
phospholipids, as observed both in vitro and in vivo [68,
69]. Conversely, myoIns epimerization is severely impaired
when insulin-sensitive tissues (muscle, fat, and liver)
become insulin resistant, and a reduced DCIns/myoIns
ratio has been suggested to represent a measure of insulin
resistance [70]. Accordingly, reduced DCIns levels are typ-
ical of urine and muscle tissue of type 2 diabetic patients
[71, 72]. Additionally, insulin resistance in both type 2
diabetic subjects with impaired glucose tolerance and
healthy controls appears to be related linearly with urinary
deficiency of DCIns [73]. Yet, insulin stimulates IPG-P
release in normal subjects but not in insulin-resistant
women with polycystic ovary syndrome (PCOS) [74].
These observations may be the result of a deficiency in
membrane-bound IPG and/or insulin resistance with
reduction of epimerase-dependent conversion of myoIns
into DCIns.
Intriguingly, in both insulin-resistant animals and
humans, the decreased availability of inositol or IPGs is
associated with the increased urinary loss of myoIns [75],
probably depending on glucose-mediated inhibition of renal
myoIns reabsorption [76]. Ultimately, a shortage of myoIns
impacts negatively on DCIns levels [77], worsening insulin
resistance. Indeed, plasma and tissue levels of DCIns and
IPGs are decreased in PCOS patients with insulin resistance
and type 2 diabetic patients [76]. However, treatment with
myoIns has not been found to lower insulin and glycaemia
in all patients with metabolic syndrome [78], strongly
suggesting that sensitivity to inositol supplementation of
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insulin-resistant subjects may depend on still unknown
additional factors.
This picture is further complicated by an intriguing
paradox that emerged in recent studies on PCOS patients
displaying insulin resistance. While insulin-resistant tissues
do suffer from a general paucity of DCIns due to the reduced
epimerization of myoIns, organs and tissues that retain their
insulin sensitivity, like the ovary [79], display increased
levels of DCIns and reduced levels of myoIns, due to the
enhanced epimerization of myoIns [80]. The impairment
of ovarian function in PCOS patients has been specifically
associated with the increase in the DCIns/myoIns ratio
within the ovary [81].
Noticeably, the role of inositol-containing phosphogly-
cans in insulin regulation has been recently questioned by
evidencing that several synthetic IPGs, opposite to natural
IPGs, are deprived of insulin-mimetic activity [82]. Since
no convincing explanation of such enigma has been pro-
posed, it can be hypothesized that synthetic IPGs lack some
critical cofactors required for the insulin-mimetic activity.
Other complications of insulin-inositol relationships
come from the demonstration that in response to insulin
stimulation of normal cells, myoIns may directly promote
activation of insulin receptor substrate (IRS) and Akt
[83]. In addition, myoIns and other inositol derivatives
enhance GLUT-4 translocation through the cell membrane
independently of insulin stimulation [84] or glucose
uptake [85].
Overactivation of IP6K1, usually triggered by insulin
stimulation, has been recently found to promote synthesis
of IP7, which inhibits Akt activity by preventing its interac-
tion with PI3K [86], thus reducing insulin sensitivity and
protein synthesis via the GSK3β and mTOR signaling path-
ways, which are both associated with insulin resistance and
weight gain [87]. On the contrary, IP6K1 knockout mice
manifest insulin sensitivity and are resistant to obesity
elicited by high-fat diet or aging.
To properly address such issues, we argue that a prelim-
inary effort should be made by performing a thorough inves-
tigation of intracellular myoIns metabolism. Indeed, once
uptaken by cells, myoIns undergoes several transformations
into key active metabolites and macromolecular complexes,
such as phosphoinositides and phospholipids. To date,
despite widespread studies carried out to identify inositol-
based effects on biological pathways, no comprehensive
metabolomic analysis has been performed so far. Only an
integrated metabolomic-genomic study would indeed pro-
vide the basic information required to identify the cellular
fate of myoIns and its gene/protein targets.
7. Conclusions
Available data suggest that inositol, through its isomers
(myoIns and DCIns) and probably some of its phosphate
intermediate metabolites and correlated enzymes (like
IP6K1), participates in insulin signaling and glucose metab-
olism, by influencing distinct pathways. Indeed, some pre-
liminary clinical reports provided compelling evidence
supporting the beneficial effects obtained with inositol in
insulin-resistant patients. Inositol reduces glycemia levels
and hyperinsulinemia, while buffering negative effects of
sustained insulin stimulation upon the adipose tissue and
the endocrine system [14, 88]. As such, myoIns has become
a reliable treatment option for insulin-resistant PCOS
patients [89, 90].
However, we are just unveiling the complex interplay
between inositol(s) and insulin-related pathways. Namely,
it is still unclear if insulin resistance depends (at least in
part) on a reduced content of membrane-bound IPGs,
on a primary defect in IPG release, or if impaired epimer-
ase activation downstream of insulin stimulation would
ultimately lead to reduced DCIns intracellular availability.
Anyhow, compelling evidence suggests that reduced
DCIns levels are associated with impaired insulin transduc-
tion in insulin-sensitive tissues, where insulin-sensitive
epimerase is unable to convert myoIns into DCIns. On the
contrary, in insulin-insensitive tissues (like the ovary and
placenta), insulin overstimulation induces an anomalous
increased conversion of myoIns into DCIns [91]. The
increased availability of DCIns in these tissues leads to sev-
eral biological dysfunctions. Indeed, experimental evidence
suggests that high DCIns levels in ovary and placenta cells
can trigger paradoxical effects on insulin signaling. In
preeclampsia-suffering women, an abnormal intracellular
amount of DCIns within the placenta promotes a specific
phosphorylation of insulin receptor substrate 1 (IRS-1) on
serine312 and leads to inhibition of the PI3K/Akt pathway
[92]. Akt inhibition worsens insulin resistance and hampers
several pathways downstream of insulin stimulation, as
observed in PCOS women whose treatment with high doses
of DCIns was shown to be detrimental [93]. Interestingly,
these results are confirmed by analysis of an experimental
PCOS mouse model in which administration of myoIns
and DCIns at ratios of 5 : 1 and 20 : 1 is detrimental for ovar-
ian morphology and function, whereas their administration
at ratios of 40 : 1 and at a lesser extent 80 : 1 rapidly restores
physiological ovarian parameters [94].
To sum up, the interplay among the different isomers of
inositol and their glycan derivatives (IPG-A and IPG-P) is
still unclear and in depth studies are warranted to fully
appreciate the contribution of inositol and inositol glycans
in insulin signaling.
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